We show that the combination therapy of adagrasib and abemaciclib led to good brain penetration and on-target activity in brain tumors carrying KRAS-G12C and CDKN2A loss and was able to provide survival benefit in an NSCLC brain metastasis model that did not respond to monotherapy. The gene discussed is CDKN2A; the disease is brain neoplasm.